Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding

This publication has 53 references indexed in Scilit:

• Acute coronary syndromes and heart failure may reflect maladaptations of trauma physiology that was shaped during pre-modern evolution
  Medical Hypotheses, 2004
• Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
  American Heart Journal, 2004
• Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
  American Heart Journal, 2003
• Molecular Determinants of the Prothrombogenic and Inflammatory Phenotype Assumed by the Postischemic Cerebral Microcirculation
  Stroke, 2003
• Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus
  Journal of Human Hypertension, 2002
• Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y ₁₂ ) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ibα Induced by Conditions of High Shear Rate
  Circulation, 2002
• Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
  Stroke, 2000
• Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhdbitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo
  Life Sciences, 1997
• Abciximab-Associated Profound Thrombocytopenia: Therapy With Immunoglobulin and Platelet Transfusion
  The American Journal of Cardiology, 1996
• THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE
  The Lancet, 1989